Journal of Clinical Oncology
Articles in this Issue
Treatment modality and anatomic site as determinants of mortality in second primary cancers after head and neck cancer: A SEER analysis.
e18100 Background: Second primary malignancies (SPMs) are a major contributor to late mortality among survivors of head an...
Paired Nectin4 expression analysis pre and post enfortumab vedotin and pembrolizumab in urothelial carcinoma.
4586 Background: Enfortumab vedotin and pembrolizumab (EVP) transformed the treatment of urothelial carcinoma (UC), yet re...
Randomized phase 2 trial of ruxolitinib in combination with radiation and temozolomide compared to radiation and temozolomide for newly diagnosed glioblastoma.
TPS2094 Background: Glioblastoma is the associated with poor outcomes despite treatment with radiation and temozolomide. T...
Lung cancer screening in septuagenarians: Do survival benefits persist with advancing age?
e20095 Background: Low-dose CT (LDCT) for lung cancer screening (LCS) reduces lung-cancer-specific mortality in high-risk...
Impact of prior treatment setting on the efficacy of rucaparib vs physician’s choice in <i>BRCA</i> -mutated castration-resistant prostate cancer (mCRPC) in TRITON3.
5054 Background: Rucaparib significantly improved radiographic progression-free survival (rPFS) versus physician’s choice...
Real-world eligibility for perioperative pembrolizumab in resectable locally advanced head and neck squamous cell carcinoma: A SEER-based analysis following KEYNOTE-689.
e18059 Background: KEYNOTE-689 demonstrated improved outcomes with perioperative pembrolizumab added to standard multimoda...
Mapping access to retinoblastoma care: Geographic disparities and service availability across Africa, and West and Central Asia.
1525 Background: Retinoblastoma, the most common childhood eye cancer, is highly manageable with prompt diagnosis and appr...
Neoadjuvant lorlatinib in stage III NSCLC harboring ALK fusion: A phase 2 multicenter study (LORIN).
8002 Background: While adjuvant alectinib has established itself as the new standard for resected anaplastic lymphoma kina...
Durvalumab or pembrolizumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy for advanced cholangiocarcinoma: A meta-analysis.
4160 Background: Cholangiocarcinoma (CCA) is a rare, aggressive malignancy of the bile duct epithelium with rising inciden...
Biomarker-driven prescribing patterns in <i>ESR1</i> <i> <sup>mut</sup> </i> ER+/HER2- metastatic breast cancer (mBC).
e23373 Background: Multiple biomarker-driven therapies are approved for ER+/HER2- mBC. Oral selective estrogen degraders (...
Artificial intelligence surrogate models to predict long-term cardiovascular effects of immune checkpoint inhibitor therapies using electrocardiograms.
12020 Background: Immune checkpoint inhibitors (ICI) revolutionized the treatment landscape for many cancers, with close t...
Early identification of patients at risk for moderate-to-severe immunotherapy-related adverse events following immune checkpoint inhibitor therapy.
e13695 Background: While immune checkpoint inhibitors (ICIs) are increasingly used for cancer treatment due to favorable t...
Assessing the accuracy and clinical utility of an algorithm-based PET/CT service for quantifying treatment response in older adults with metastatic cancer.
e13649 Background: There is substantial variability in PET/CT interpretation, influenced by technical, procedural, and rea...
NeoRay phase IIa results: A study of [ <sup>177</sup> Lu]Lu-NeoB ( <sup>177</sup> Lu-NeoB) in pts with advanced solid tumors overexpressing gastrin-releasing peptide receptor (GRPR).
3095 Background: GRPR is overexpressed in many solid tumors. NeoB binds to GRPR with high affinity and can be radiolabeled...
Assessment of killer-cell immunoglobulin-like receptor (KIR) polymorphisms and their HLA-ligands in epithelial ovarian cancer (EOC).
e17580 Background: EOC carcinogenesis involves the progressive accumulation of genetic, epigenetic, and molecular alterati...
Secondary multiple myeloma and antecedent cancer lineage.
e22622 Background: The emergence of second primary malignancies (SPM) constitutes a growing clinical burden. However, data...
Myeloablative vs reduced-intensity conditioning in PTCy-based allogeneic HCT: A CIBMTR analysis.
6563 Background: Post-transplant cyclophosphamide (PTCy) is widely used in matched unrelated and haploidentical HCT. Howev...
Real-world study of first-line immunotherapy for EGFR/ALK wild-type advanced NSCLC: Analysis from the China National Cancer Center database.
e20584 Background: Immune checkpoint inhibitor (ICI) monotherapy (mono) or combined with chemotherapy (CT) is standard fir...
PCSK9 inhibitors and association with lower risk of metastasis.
10588 Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that regulates degradation of...
Impact of a whole-food plant-based diet (WFPBD) on weight and metabo-inflammation in men with prostate cancer (PC) receiving androgen deprivation therapy (ADT): A multi-center randomized control trial.
5098 Background: Obesity promotes a chronic inflammatory state associated with PC progression. ADT can cause weight gain,...
Impact of an electronic best practice advisory on fertility preservation referral and consultation rates in pediatric oncology: A pre–post implementation study.
e13529 Background: Fertility preservation (FP) counseling is recommended as standard of care for pediatric oncology patien...
Predictive value of PET-CT and tumor biology for pathological complete response in triple-negative breast cancer treated with neoadjuvant pembrolizumab: A real-world analysis.
e12589 Background: Pembrolizumab combined with chemotherapy improves pathological complete response (pCR) in early-stage t...
Age-based differences in outcomes among small cell lung cancer patients treated with tarlatamab.
8069 Background: Tarlatamab has durable antitumor activity in patients with previously treated Small Cell Lung Cancer (SCL...
FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET mAb) in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC).
TPS6132 Background: Patients with HPV negative R/M HNSCC have a worse median overall survival (OS) than those with HPV pos...
Intracranial efficacy of osimertinib in <i>EGFR</i> -mutated non–small cell lung cancer with brain metastases: A meta-analysis.
e20765 Background: Brain metastases are a major cause of morbidity and mortality in EGFR-mutated non-small cell lung cance...